Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Protagenic Therapeutics ( (PTIX) ).
On July 18, 2025, Protagenic Therapeutics, Inc. appointed Timothy R. Wright as a new member of its Board of Directors, effective immediately, to serve as a Class II director until the 2026 annual meeting of shareholders. Mr. Wright, recognized as an independent director, brings extensive experience from his roles at Isosceles, BIORG, INC, and MiMedX, among others, enhancing the company’s governance with his diverse background in the pharmaceutical and medical industries.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Average Trading Volume: 1,942,384
Technical Sentiment Signal: Sell
Current Market Cap: $2.93M
For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.